Novartis AG is 13.4x more valuable than Royalty Pharma plc by market capitalization ($283.13 B vs $21.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RPRX | NVS |
|---|---|---|
| Market cap | $21.16 B | $283.13 B |
| US-listed rank | #600 | #47 |
| Revenue (latest FY) | $2.38B | - |
| Net income (latest FY) | $770.95M | - |
| Net margin | 32.4% | - |
| P/E (trailing FY) | 27.4 | - |
| SEC filings | 588 | 947 |
Novartis AG is 13.4x more valuable than Royalty Pharma plc by market capitalization ($283.13 B vs $21.16 B).
Full pages: Royalty Pharma plc and Novartis AG, or browse the full rankings.